ATE349213T1 - Nasale pharmazeutische zusammensetzung von piribedil - Google Patents
Nasale pharmazeutische zusammensetzung von piribedilInfo
- Publication number
- ATE349213T1 ATE349213T1 AT04767691T AT04767691T ATE349213T1 AT E349213 T1 ATE349213 T1 AT E349213T1 AT 04767691 T AT04767691 T AT 04767691T AT 04767691 T AT04767691 T AT 04767691T AT E349213 T1 ATE349213 T1 AT E349213T1
- Authority
- AT
- Austria
- Prior art keywords
- piribedil
- pharmaceutical composition
- nasal pharmaceutical
- nasal
- composition
- Prior art date
Links
- OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical group C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229960004310 piribedil Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0308712A FR2857594B1 (fr) | 2003-07-17 | 2003-07-17 | Composition pharmaceutique pour l'administration par voie nasale de piribedil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE349213T1 true ATE349213T1 (de) | 2007-01-15 |
Family
ID=33548200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04767691T ATE349213T1 (de) | 2003-07-17 | 2004-07-16 | Nasale pharmazeutische zusammensetzung von piribedil |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20060204449A1 (de) |
| EP (1) | EP1653963B1 (de) |
| JP (1) | JP2007516947A (de) |
| KR (1) | KR100807480B1 (de) |
| CN (1) | CN100540004C (de) |
| AR (1) | AR046808A1 (de) |
| AT (1) | ATE349213T1 (de) |
| AU (1) | AU2004258714A1 (de) |
| BR (1) | BRPI0412681A (de) |
| CA (1) | CA2532631C (de) |
| CY (1) | CY1106013T1 (de) |
| DE (1) | DE602004003955T2 (de) |
| DK (1) | DK1653963T3 (de) |
| EA (1) | EA011041B1 (de) |
| ES (1) | ES2279435T3 (de) |
| FR (1) | FR2857594B1 (de) |
| GE (1) | GEP20074259B (de) |
| HR (1) | HRP20070081T5 (de) |
| MA (1) | MA27864A1 (de) |
| MX (1) | MXPA06000641A (de) |
| MY (1) | MY137747A (de) |
| NO (1) | NO332776B1 (de) |
| NZ (1) | NZ544460A (de) |
| PL (1) | PL1653963T3 (de) |
| PT (1) | PT1653963E (de) |
| SI (1) | SI1653963T1 (de) |
| UA (1) | UA85193C2 (de) |
| WO (1) | WO2005009442A1 (de) |
| ZA (1) | ZA200600240B (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010013393A (es) | 2008-06-06 | 2011-06-21 | Pharma Two B Ltd | Composiciones farmaceuticas para el tratamiento de la enfermedad de parkinson. |
| WO2014141280A1 (en) * | 2013-03-13 | 2014-09-18 | Abital Pharma Pipelines Ltd. | Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease |
| IT201800005117A1 (it) | 2018-05-07 | 2019-11-07 | Acqua irradiata con energie elettromagnetiche per uso terapeutico |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69434304T2 (de) * | 1993-03-26 | 2005-12-29 | Merkus, Franciscus Wilhelmus H.M. | Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin |
| BE1007402A5 (nl) * | 1993-03-26 | 1995-06-06 | Adir | Nasale farmaceutische preparaten met progestagene stof. |
| FR2710268B1 (fr) * | 1993-09-22 | 1995-10-20 | Adir | Utilisation de beta-cyclodextrines partiellement méthylées comme promoteurs d'absorption dans la préparation de compositions pharmaceutiques pour l'administration transcutanée de principes actifs. |
| FR2710265B1 (fr) * | 1993-09-22 | 1995-10-20 | Adir | Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs. |
| FR2742989B1 (fr) * | 1995-12-29 | 1998-01-23 | Adir | Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs |
| NZ501321A (en) * | 1997-03-26 | 2001-04-27 | Franciscus W | Nasal Melatonin composition |
| EP0900567A3 (de) * | 1997-09-05 | 2001-05-02 | Pfizer Products Inc. | Quinazolin-4-on AMPA Antagonisten zur Behandlung von motorischen Fehlfunktionen verbunden mit Dopaminagonist Therapie |
| US20020002175A1 (en) * | 2000-09-19 | 2002-01-03 | Charanjit Behl | Nasal delivery of apomorphine in combination with glycol derivatives |
| US20040028613A1 (en) * | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
| FR2827516B1 (fr) * | 2001-07-19 | 2003-09-19 | Servier Lab | Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone |
-
2003
- 2003-07-17 FR FR0308712A patent/FR2857594B1/fr not_active Expired - Fee Related
-
2004
- 2004-07-15 AR ARP040102489A patent/AR046808A1/es unknown
- 2004-07-15 MY MYPI20042838A patent/MY137747A/en unknown
- 2004-07-16 KR KR1020067001141A patent/KR100807480B1/ko not_active Expired - Fee Related
- 2004-07-16 UA UAA200601630A patent/UA85193C2/ru unknown
- 2004-07-16 ZA ZA200600240A patent/ZA200600240B/en unknown
- 2004-07-16 DE DE602004003955T patent/DE602004003955T2/de not_active Expired - Lifetime
- 2004-07-16 WO PCT/FR2004/001867 patent/WO2005009442A1/fr not_active Ceased
- 2004-07-16 CN CNB2004800197495A patent/CN100540004C/zh not_active Expired - Fee Related
- 2004-07-16 EA EA200600172A patent/EA011041B1/ru not_active IP Right Cessation
- 2004-07-16 HR HR20070081T patent/HRP20070081T5/xx unknown
- 2004-07-16 PL PL04767691T patent/PL1653963T3/pl unknown
- 2004-07-16 NZ NZ544460A patent/NZ544460A/en not_active IP Right Cessation
- 2004-07-16 JP JP2006519966A patent/JP2007516947A/ja active Pending
- 2004-07-16 GE GEAP20049239A patent/GEP20074259B/en unknown
- 2004-07-16 AU AU2004258714A patent/AU2004258714A1/en not_active Abandoned
- 2004-07-16 ES ES04767691T patent/ES2279435T3/es not_active Expired - Lifetime
- 2004-07-16 MX MXPA06000641A patent/MXPA06000641A/es active IP Right Grant
- 2004-07-16 DK DK04767691T patent/DK1653963T3/da active
- 2004-07-16 CA CA2532631A patent/CA2532631C/fr not_active Expired - Fee Related
- 2004-07-16 AT AT04767691T patent/ATE349213T1/de active
- 2004-07-16 EP EP04767691A patent/EP1653963B1/de not_active Expired - Lifetime
- 2004-07-16 US US10/564,139 patent/US20060204449A1/en not_active Abandoned
- 2004-07-16 BR BRPI0412681-5A patent/BRPI0412681A/pt not_active IP Right Cessation
- 2004-07-16 SI SI200430163T patent/SI1653963T1/sl unknown
- 2004-07-16 PT PT04767691T patent/PT1653963E/pt unknown
-
2005
- 2005-12-27 MA MA28688A patent/MA27864A1/fr unknown
-
2006
- 2006-02-16 NO NO20060743A patent/NO332776B1/no not_active IP Right Cessation
-
2007
- 2007-02-13 CY CY20071100190T patent/CY1106013T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60201988D1 (de) | Pharmazeutische dosierungsform von amorphem nilfenavir mesylat | |
| DE60201859D1 (de) | Pharmazeutische Verwendung von N-Carbamoylazol-Derivate | |
| CY2017048I1 (el) | Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης | |
| ATE380544T1 (de) | Umhüllte feste darreichungsform | |
| DE60333294D1 (de) | Kontrollierte verabreichung von arzneien | |
| EP1513825A4 (de) | Antituberkulöses arzneimittel: zusammensetzungen und verfahren | |
| EP1603593A4 (de) | Pharmazeutische zusammensetzung | |
| CY2018005I2 (el) | Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης | |
| DE60213592D1 (de) | Flüssige pharmazeutische zusammensetzung | |
| EP1425019A4 (de) | Pharmazeutische zusammensetzung | |
| DE60312049D1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff | |
| ATE309789T1 (de) | Darreichungsform von ibuprofen-natrium | |
| EP1689419A4 (de) | Pharmazeutische zusammensetzungen mit niedrigen dosen von desmopressin | |
| ATE477814T1 (de) | Stabile faktor-viii enthaltende pharmazeutische zusammensetzung | |
| ITMI20021684A1 (it) | Composizione farmaceutica di peptide nasale | |
| PL361518A1 (pl) | Zastosowanie substancji oraz kompozycja farmaceutyczna | |
| BRPI0312413A2 (pt) | compostos, composições farmacêuticas contendo os mesmos, e método de utilização para os mesmos | |
| DE60217390D1 (de) | Bicalutamid enthaltende pharmazeutische zusammensetzung | |
| ATE507831T1 (de) | Melatonin enthaltende pharmazeutische formulierung | |
| NO20054662D0 (no) | Farmasoytisk sammensetning omfattende 5-metyl-2-2'-(klor-6'-fluoranilin)fenyleddiksyre | |
| DE112004001618D2 (de) | Pharmazeutischer Wirkstoff gegen Tumorerkrankungen | |
| ATE439354T1 (de) | Pharmazeutische salze von reboxetin | |
| DE602004003955D1 (de) | Nasale pharmazeutische zusammensetzung von piribedil | |
| DE502004009045D1 (de) | Injizierbare darreichungsform von flupirtin | |
| ATE443512T1 (de) | Pharmazeutische zusammensetzung von piperazinderivaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1653963 Country of ref document: EP |